Visit our Location
11860 Vista Del Sol Dr Suite 105,
El Paso, TX 79936
Give us a Call
+1 (915) 412-6680
Send us a Message
[email protected]
Opening Hours
Mon-Thu: 7 AM - 7 PM
Fri - Sun: Closed

Tag: cardiovascular disease

ChiroMedBlogcardiovascular disease

Chiropractic Rehabilitation Benefits for You and Your Heart Health


Find out how chiropractic rehabilitation can play a crucial role in enhancing your heart health and wellness journey.

Abstract

Heart health affects far more than the heart itself. The cardiovascular system delivers oxygen, nutrients, hormones, and other essential substances to muscles, joints, nerves, connective tissues, and organs throughout the body. When cardiovascular health declines, people may experience fatigue, reduced exercise tolerance, weakness, swelling, shortness of breath, and difficulty remaining physically active.

These changes can have important consequences for the musculoskeletal system. Reduced activity can contribute to deconditioning, muscle weakness, stiffness, poor mobility, and greater difficulty managing chronic neck, back, and joint pain. Research also shows an important association between cardiovascular disease and chronic musculoskeletal pain, although this relationship is complex and does not prove that one condition directly causes the other (Oliveira et al., 2020; Rönnegård et al., 2026).

Chiropractic care should not be presented as a treatment for coronary artery disease, cardiomyopathy, heart failure, or other cardiovascular diseases. Instead, its potential role is supportive: helping appropriately selected patients address musculoskeletal pain, mobility limitations, biomechanics, and physical function so they can participate more comfortably in medically appropriate activity and rehabilitation.

From Dr. Alexander Jimenez, DC, APRN, FNP-BC’s clinical perspective, this distinction is especially important. Musculoskeletal complaints should be evaluated within the context of the whole patient because pain, weakness, fatigue, exercise intolerance, swelling, neuropathy, or other symptoms can sometimes overlap with systemic disease.

Why Heart Health Matters to the Whole Body

The heart and vascular system form the body’s transportation network. With every heartbeat, blood carries oxygen and nutrients to tissues while helping remove carbon dioxide and metabolic waste.

Healthy circulation supports:

  • Muscle contraction and recovery
  • Nerve function
  • Physical endurance
  • Tissue metabolism
  • Exercise capacity
  • Joint and connective-tissue health
  • Brain function
  • Kidney and organ function
  • Healing and rehabilitation

Cardiovascular disease remains one of the world’s largest health burdens. Important modifiable risk factors include physical inactivity, unhealthy dietary patterns, tobacco exposure, elevated blood pressure, abnormal blood glucose, abnormal blood lipids, and excess body weight (World Health Organization [WHO], n.d.).

Heart health and movement therefore have a two-way relationship. A healthier cardiovascular system makes physical activity easier, while regular physical activity can help improve blood pressure, glucose regulation, weight management, cardiovascular fitness, and overall physical function (American Heart Association [AHA], 2024).

The Heart-Musculoskeletal Connection

The musculoskeletal system includes muscles, bones, joints, tendons, ligaments, and connective tissues. These structures require adequate circulation and regular mechanical loading to function well.

When cardiovascular disease reduces a person’s ability to exercise, a cycle can develop:

Cardiovascular limitations -> fatigue or exercise intolerance -> less movement -> muscle weakness and deconditioning -> reduced mobility -> greater difficulty exercising

This relationship becomes especially important for patients already living with back pain, neck pain, arthritis, obesity, diabetes, or other chronic conditions.

The WHO notes that musculoskeletal conditions can significantly restrict mobility and participation in everyday activities and commonly coexist with other noncommunicable diseases, including cardiovascular disease (WHO, 2022).

That overlap deserves clinical attention.

Chronic Musculoskeletal Pain and Cardiovascular Disease

Researchers have found significant associations between chronic musculoskeletal pain and cardiovascular disease.

In a systematic review and meta-analysis, Oliveira et al. (2020) found that adults with chronic musculoskeletal pain were more likely to report cardiovascular disease than people without chronic musculoskeletal pain.

More recent evidence strengthens the case for clinicians to pay attention to this connection. A 2026 systematic review and meta-analysis found that chronic widespread pain was associated with increased risk of incident atherosclerotic cardiovascular disease. The authors emphasized that the available studies were heterogeneous and that the relationship should not automatically be interpreted as direct causation (Rönnegård et al., 2026).

Several factors may help explain this overlap.

Physical Inactivity

Pain can make people reluctant to move. A patient with chronic low back, hip, or knee pain may gradually walk less, exercise less, and spend more time sitting.

Physical inactivity is itself an important cardiovascular risk factor. Regular physical activity, by contrast, supports cardiovascular fitness while helping maintain muscle strength, bone health, mobility, body composition, and metabolic health (AHA, 2024).

Obesity and Metabolic Disease

Obesity can increase mechanical stress on weight-bearing joints while also increasing cardiovascular and metabolic risk.

A patient may therefore have several overlapping problems:

  • Low back or knee pain
  • Reduced mobility
  • Weight gain
  • Hypertension
  • Insulin resistance or diabetes
  • Abnormal cholesterol
  • Poor sleep
  • Physical deconditioning

Treating only one piece of this picture may leave important contributors unaddressed.

Chronic Inflammation

Inflammatory processes are involved in several musculoskeletal disorders and also play an important role in atherosclerosis and cardiovascular disease.

However, inflammation should not be used as a catch-all explanation. Cardiovascular disease is multifactorial, and individual risk depends on genetics, age, blood pressure, metabolic health, smoking, activity, diet, kidney function, medications, and many other factors.

Stress, Sleep, and Pain

Chronic pain may disrupt sleep and increase psychological stress. Poor sleep and chronic stress can then make pain harder to manage and may interfere with healthy activity, nutrition, weight control, and cardiovascular risk management.

The result can become another cycle:

Pain -> poor sleep and stress -> reduced activity -> metabolic strain -> greater physical deconditioning -> more difficulty managing pain

Heart Failure and the Musculoskeletal System

Heart failure provides a clear example of why cardiovascular and musculoskeletal health cannot always be separated.

Heart failure is a clinical syndrome in which abnormalities in cardiac structure or function can lead to symptoms such as shortness of breath, fatigue, exercise intolerance, and fluid retention (Heidenreich et al., 2022).

These symptoms can substantially reduce activity.

When patients move less, they may lose strength and endurance. The original clinical material from Dr. Jimenez similarly emphasizes that patients with chronic heart failure can experience deconditioning, muscle loss, postural changes, and secondary musculoskeletal complaints, making mobility and rehabilitation important supportive considerations.

For medically stable patients, appropriately prescribed exercise and cardiac rehabilitation can be valuable components of care. Cardiac rehabilitation is medically supervised and designed to improve physical, psychological, and social function in people with qualifying cardiovascular conditions (AHA, n.d.).

Chiropractic Care & Metabolism *The Hidden Link*- Video

Where Chiropractic Care Fits

An important distinction must be made:

Chiropractic care does not replace cardiology or evidence-based medical treatment for cardiovascular disease.

A chiropractic adjustment does not open a blocked coronary artery, reverse cardiomyopathy, replace heart-failure medications, or substitute for cardiac rehabilitation.

The more appropriate question is:

Can musculoskeletal care help a patient move and function better as part of a larger cardiovascular wellness or rehabilitation strategy?

For selected patients, the answer may be yes.

1. Addressing Musculoskeletal Pain

Back, neck, hip, and other musculoskeletal pain can block physical activity.

Chiropractic and rehabilitative care may address mechanical musculoskeletal complaints so patients can improve their tolerance for movement when exercise has been medically cleared.

The objective is not to “treat the heart” through the spine. It is to address musculoskeletal obstacles that may interfere with healthy movement.

2. Improving Mobility

Restricted spinal or joint movement can make walking, exercising, bending, lifting, and performing daily activities uncomfortable.

Depending on the patient’s diagnosis and cardiovascular status, a musculoskeletal program may include:

  • Appropriate chiropractic manipulation or mobilization
  • Gentle joint mobilization
  • Soft-tissue techniques
  • Corrective exercises
  • Flexibility work
  • Postural training
  • Strengthening
  • Balance exercises
  • Ergonomic modifications
  • Progressive rehabilitation

Improved mobility may make it easier for some patients to follow medically appropriate exercise recommendations.

3. Supporting Exercise Participation

Physical activity benefits cardiovascular and musculoskeletal health simultaneously.

The AHA recommends that most adults aim for at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of vigorous activity per week, along with muscle-strengthening activity; people with chronic medical conditions should discuss appropriate activity with their healthcare professionals (AHA, 2024).

For patients with established cardiovascular disease, the treating medical or cardiac rehabilitation team may need to individualize the exercise prescription.

Chiropractic rehabilitation can complement this process by addressing musculoskeletal limitations that interfere with walking, strengthening, stretching, or other prescribed activities.

What About Chiropractic Care and the Autonomic Nervous System?

The relationship between spinal manipulation and autonomic nervous system activity has received considerable research attention.

Earlier research reported short-term changes in measures such as heart-rate variability following certain manual interventions (Borges et al., 2018). However, newer systematic-review evidence is more cautious.

A 2023 systematic review and meta-analysis found low-quality evidence that spinal manipulation generally did not produce significant changes across autonomic measures. However, it reported limited findings involving cervical manipulation and some heart-rate variability measures (Picchiottino et al., 2023).

Therefore, claims that chiropractic adjustments directly “balance the autonomic nervous system,” lower cardiovascular risk, or treat heart disease go beyond what current evidence can confidently support.

A better evidence-based interpretation is that chiropractic care can be considered primarily for its musculoskeletal role, while autonomic effects remain an area of continuing investigation.

Dr. Jimenez’s Clinical Perspective: Look Beyond the Pain

A key principle in Dr. Alexander Jimenez’s clinical approach is that musculoskeletal symptoms should not be viewed in isolation.

His professional materials emphasize integrative, evidence-informed care combining musculoskeletal evaluation, rehabilitation, functional health considerations, and collaboration across healthcare disciplines. His original heart-health material similarly describes a multidisciplinary approach in which cardiovascular conditions receive appropriate medical oversight while chiropractic and rehabilitative care address biomechanics, mobility, and musculoskeletal function.

This matters because a person who enters a chiropractic clinic complaining of back pain may also report:

  • Unusual shortness of breath
  • New exercise intolerance
  • Chest pressure
  • Dizziness
  • Unexplained fatigue
  • Palpitations
  • New swelling in both legs
  • Fainting
  • Unusual weakness

These findings should not simply be attributed to spinal dysfunction.

They may require medical or cardiovascular evaluation.

This “whole-patient” mindset is particularly important when musculoskeletal complaints coexist with hypertension, diabetes, obesity, dyslipidemia, kidney disease, previous heart attack, known coronary artery disease, or heart failure.

Dr. Jimenez’s professional profile likewise describes an integrative approach focused on mobility, musculoskeletal rehabilitation, functional health, and collaboration among healthcare professionals. (Jimenez, n.d.)

Musculoskeletal Clues Can Sometimes Point Beyond the Spine

Some systemic diseases can present with musculoskeletal or neurological symptoms.

The source clinical material highlights cardiac amyloidosis as an important example. Certain patients may develop bilateral carpal tunnel syndrome, peripheral neuropathy, autonomic symptoms, or lumbar spinal stenosis before cardiac disease becomes obvious.

This does not mean that ordinary carpal tunnel syndrome or spinal stenosis indicates heart disease.

Most cases do not.

Instead, it demonstrates why clinicians should consider the complete clinical picture rather than assuming every painful musculoskeletal symptom originates exclusively from mechanical dysfunction.

When Musculoskeletal Pain Could Be a Cardiovascular Warning Sign

Chest, shoulder, upper-back, arm, neck, or jaw discomfort is not always musculoskeletal.

Cardiac ischemia may sometimes produce discomfort outside the chest. The original clinical material emphasizes that symptoms may occur relatively late in the ischemic cascade and may include shortness of breath or pain involving the arm or jaw.

New or unexplained chest pressure or pain accompanied by symptoms such as shortness of breath, sweating, nausea, faintness, or radiating arm or jaw discomfort requires urgent medical evaluation.

This is another reason musculoskeletal clinicians should screen carefully rather than treating every upper-body pain complaint as a mechanical problem.

Building a Heart-Musculoskeletal Health Strategy

A comprehensive approach should address cardiovascular and musculoskeletal health together rather than viewing them as unrelated systems.

For an appropriate patient, the plan may involve medical evaluation and cardiovascular risk management, along with gradual physical activity, resistance exercise, mobility work, weight management, nutritious eating, adequate sleep, stress management, and treatment of limiting musculoskeletal pain.

The cardiovascular team manages cardiovascular disease.

The musculoskeletal team helps remove physical barriers to movement.

Nutrition and metabolic care address relevant risk factors.

Rehabilitation helps rebuild function.

The patient becomes the center connecting these disciplines.

Movement Is the Common Ground

One of the strongest connections between cardiovascular and musculoskeletal health is movement.

Physical activity helps condition the cardiovascular system while supporting muscle strength, bone health, balance, mobility, glucose regulation, and body-weight management (AHA, 2024).

But telling someone to “exercise more” is not always enough.

Someone with severe low back pain, knee osteoarthritis, neck pain, weakness, or poor balance may struggle to follow that advice.

This is where appropriate musculoskeletal treatment can have an important supportive role. If pain and movement limitations decrease, the patient may be better positioned to participate in walking, strengthening, cardiac rehabilitation, or another medically approved activity program.

The Bottom Line

Heart health and musculoskeletal health are deeply connected through movement, physical conditioning, metabolism, inflammation, and overall functional capacity.

Chronic cardiovascular disease can contribute to fatigue, reduced activity, exercise intolerance, and physical deconditioning. At the same time, chronic musculoskeletal pain may reduce movement and, in population research, is associated with a greater burden of cardiovascular disease (Oliveira et al., 2020; Rönnegård et al., 2026).

Chiropractic care should not be promoted as a treatment for heart disease. Its strongest role in this setting is supportive: addressing appropriate musculoskeletal pain and mobility limitations, improving physical function, and helping patients participate in medically appropriate exercise and rehabilitation.

From the integrative clinical perspective used by Dr. Alexander Jimenez, DC, APRN, FNP-BC, the larger lesson is to look beyond a single painful joint or spinal region. A patient’s cardiovascular, metabolic, neurological, and musculoskeletal systems interact. Good care recognizes those connections, identifies red flags, respects professional boundaries, and coordinates treatment when multiple systems are involved.

Supporting the patient’s ability to move safely may ultimately support much more than the spine. It can become part of a broader strategy for maintaining cardiovascular fitness, strength, independence, and long-term quality of life.

References

American Heart Association. (2024). American Heart Association recommendations for physical activity in adults and kids.

American Heart Association. (n.d.). Cardiac rehabilitation for heart failure.

Borges, B. L. A., Bortolazzo, G. L., & Pasin Neto, H. (2018). Effects of spinal manipulation and myofascial techniques on heart rate variability: A systematic review. Journal of Bodywork and Movement Therapies, 22(1), 203-208. https://doi.org/10.1016/j.jbmt.2017.09.025

Heidenreich, P. A., Bozkurt, B., Aguilar, D., et al. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation, 145(18), e895-e1032. https://doi.org/10.1161/CIR.0000000000001063

Jimenez, A. (n.d.). Dr. Alexander Jimenez, DC, APRN, FNP-BC – Professional profile. LinkedIn.

Oliveira, C. B., Maher, C. G., Franco, M. R., Kamper, S. J., Williams, C. M., Silva, F. G., & Pinto, R. Z. (2020). Co-occurrence of chronic musculoskeletal pain and cardiovascular diseases: A systematic review with meta-analysis. Pain Medicine, 21(6), 1106-1121. https://doi.org/10.1093/pm/pnz217

Picchiottino, M., et al. (2023). Effectiveness of spinal manipulation in influencing the autonomic nervous system: A systematic review and meta-analysis.

Rönnegård, A.-S., Schillemans, T., Äng, B., Boersma, K., Ärnlöv, J., & Tseli, E. (2026). Chronic widespread pain and the risk of cardiovascular disease: A systematic review and meta-analysis. Pain, 167(6), 1295-1307. https://doi.org/10.1097/j.pain.0000000000003965

World Health Organization. (2022). Musculoskeletal health.

World Health Organization. (n.d.). Cardiovascular diseases.

SEO Tags

heart health, chiropractic care, cardiovascular health, musculoskeletal health, chiropractic and heart health, heart disease and musculoskeletal pain, chronic pain and cardiovascular disease, cardiovascular disease, musculoskeletal pain, chronic back pain, neck pain, heart failure, physical activity, cardiac rehabilitation, mobility, exercise tolerance, cardiovascular fitness, integrative chiropractic care, integrative medicine, functional medicine, spinal health, joint health, muscle health, chronic inflammation, metabolic health, obesity and heart disease, hypertension, diabetes, cardiovascular risk factors, exercise and heart health, mobility and heart health, chiropractic rehabilitation, musculoskeletal rehabilitation, heart disease rehabilitation, chronic pain and heart disease, cardiovascular wellness, whole-body health, Dr. Alexander Jimenez, Dr. Alex Jimenez, DC APRN FNP-BC, ChiroMed, El Paso chiropractor, El Paso chiropractic care, El Paso integrative medicine, El Paso heart health, El Paso rehabilitation

Cardiometabolic Research Advances Using GLP-1 Receptor Therapy


Find out about GLP-1 receptor therapy on cardiometabolic health and its revolutionary role in modern medicine and patient care.

Abstract

Hello, I’m Dr. Alex Jimenez, and I am honored to share transformative insights into managing cardiovascular and metabolic conditions, such as type 2 diabetes. This educational post explores a significant shift in our medical understanding, moving from a purely glucose-centric model to a comprehensive, risk-reduction strategy. Here, we will journey through the latest findings from leading researchers, backed by robust, evidence-based studies, to understand this new paradigm. We’ll delve into the mechanisms of two groundbreaking classes of medications—SGLT2 inhibitors and GLP-1 receptor agonists—and their profound benefits for cardiovascular and renal health, often independent of their glucose-lowering effects. We will also discuss how our multidisciplinary team at Injury Medical Clinic PA, including the invaluable medical direction of Dr. Maria Guadalupe Cardenas, MD, integrates these advancements with integrative chiropractic care, functional medicine, and rehabilitation to provide a truly holistic treatment plan for our patients in El Paso, Texas. This post aims to illuminate the interconnectedness of cardiac, metabolic, and kidney health and present a collaborative path forward for optimal patient outcomes.

Our Collaborative and Integrative Practice at Injury Medical Clinic PA

Before we delve into the clinical science, I want to take a moment to explain our unique approach to patient care here in El Paso, Texas. At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, we have built a truly multidisciplinary practice. I am Dr. Alex Jimenez, and my credentials include DC, APRN, FNP-BC, CFMP, IFMCP, ATN, and CCST. My passion lies in functional medicine and chiropractic care, focusing on the body’s innate ability to heal and the musculoskeletal system’s foundational role in overall health.
A cornerstone of this model is my collaboration with Dr. Maria Guadalupe Cardenas, MD. With over 40 years of experience as a board-certified internist, Dr. Cardenas serves as our Medical Director and Collaborative Physician (NPI #1164426749, Texas MD License #J2933). Her extensive expertise in internal medicine provides essential medical oversight and direction, allowing us to seamlessly merge advanced medical protocols with chiropractic, functional medicine, rehabilitation, and personal injury care.
Our model is built on the synergy between different disciplines:

  • Medical Oversight (Dr. Cardenas): Provides diagnoses, prescribes medications like the advanced therapies we will discuss today, and oversees the overall medical treatment plan, ensuring patient safety and efficacy.
  • Chiropractic and Functional Medicine (Dr. Jimenez): I focus on identifying and addressing the root causes of dysfunction. Through chiropractic adjustments, we restore proper nerve function and biomechanics. With functional medicine, we analyze a patient’s genetics, lifestyle, and environment to correct underlying imbalances in metabolism, inflammation, and gut health.
  • Integrated Services: Together, we manage personal injury cases, rehabilitation, nutritional counseling, and chronic disease management. This team-based approach ensures that a patient with diabetes, for example, not only receives the latest medications but also benefits from dietary overhauls, targeted supplementation, and structural care to improve insulin sensitivity and reduce systemic inflammation. This is the essence of integrative medicine—uniting the best of multiple worlds for superior patient outcomes.

The Critical Link Between Diabetes and Cardiovascular Disease

For a long time, the primary focus in managing type 2 diabetes was on lowering blood glucose. While important, this approach was incomplete. We now have an overwhelming body of evidence showing that people with diabetes face a significantly elevated risk for Atherosclerotic Cardiovascular Disease (ASCVD), which includes coronary heart disease, stroke, and peripheral arterial disease. In fact, ASCVD is the leading cause of death for individuals with diabetes.

  • Consider this startling fact: over 70% of individuals with diabetes over the age of 65 will likely succumb to heart disease or a stroke.
  • Following a heart attack (myocardial infarction or MI), people with diabetes have a much higher mortality risk and a poorer long-term prognosis.
  • These grim outcomes persist even when blood sugar levels are well-controlled, and they affect individuals with both type 1 and type 2 diabetes.

This reality has forced a paradigm shift in how we manage these interconnected conditions. The focus has expanded from aggressive glucose reduction to a holistic strategy to reduce overall cardiovascular and renal risk. This involves managing not just blood sugar, but also blood pressure, cholesterol levels, weight, physical activity, and smoking cessation. For the first time in my career, all the major guideline-issuing bodies—including the American College of Cardiology (ACC), the American Heart Association (AHA), the American Diabetes Association (ADA), and the Kidney Disease: Improving Global Outcomes (KDIGO)—are in complete agreement on this new, integrated approach to care. This consensus marks a monumental step forward, allowing us to view and treat our patients through a unified, comprehensive lens.

Rethinking Treatment Algorithms: A Risk-Based Approach

This new paradigm is reflected in the latest treatment algorithms from the American Diabetes Association. The guidelines now emphasize a risk-stratified approach. For any patient with type 2 diabetes who has established ASCVD, heart failure, chronic kidney disease (CKD), or is at high risk for developing these conditions, the recommendation is to concurrently address all risk factors and prioritize specific classes of medications.
The algorithm directs us to move beyond traditional first-line agents like metformin alone and immediately consider two powerful classes of drugs:

  1. SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitors
  2. GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists

These medications are now recommended as foundational therapies for high-risk patients precisely because they have demonstrated proven cardiovascular (CV) benefits in large-scale clinical trials. The choice between them, or the decision to use them in combination, depends on patient-specific factors, comorbidities, and preferences. This marks a significant departure from simply trying to lower the A1C; it’s about proactively protecting the heart and kidneys.

The History and Evolution of Diabetes Medication Trials

How did we arrive at this pivotal moment? The story begins around 2008, when the U.S. Food and Drug Administration (FDA) issued mandatory guidance for all new antidiabetic medications. The FDA required pharmaceutical companies to conduct long-term Cardiovascular Outcomes Trials (CVOTs). The primary goal was to ensure that these new drugs did not increase the risk of Major Adverse Cardiovascular Events (MACE)—a composite of non-fatal heart attack, non-fatal stroke, and cardiovascular death.
This mandate was a direct response to past experiences where certain drugs, such as rosiglitazone (Avandia) and others like Vioxx, were later found to cause cardiovascular harm. Earlier studies were often too short, underpowered, or poorly designed to detect these risks. The FDA’s new requirement forced the industry to conduct large, well-designed, placebo-controlled trials that were robust enough to demonstrate safety or non-inferiority.
What happened next was truly surprising. As the results of these CVOTs began to be published, starting with the EMPA-REG OUTCOME trial for empagliflozin (Jardiance) in 2015, researchers discovered something extraordinary. These new drugs weren’t just safe—some of them were actively protective.

  • Empagliflozin (Jardiance), an SGLT2 inhibitor, was the first to show a significant reduction in MACE, CV death, and hospitalization for heart failure.
  • Liraglutide (Victoza), a GLP-1 receptor agonist, followed in 2016 with the LEADER trial, also demonstrating significant cardiovascular benefits.

These unexpected findings of superiority, not just safety, were game-changers. They provided the evidence needed to completely overhaul the clinical guidelines and place these drug classes at the forefront of managing patients with cardiovascular, metabolic, and renal disease.

A Deeper Dive into SGLT2 Inhibitors

Let’s explore the SGLT2 inhibitor class more closely. These medications work by blocking glucose reabsorption in the kidney, causing excess sugar to be excreted in the urine. While this helps lower blood glucose, their profound cardiovascular and renal benefits appear to stem from multiple other mechanisms.

Landmark Cardiovascular Outcomes Trials for SGLT2 Inhibitors

Several major CVOTs have established the benefits of this class:

  • EMPA-REG OUTCOME (empagliflozin/Jardiance): This trial was a watershed moment. It showed a highly statistically significant reduction in MACE, CV death, and hospitalization for heart failure.
  • CANVAS Program (canagliflozin/Invokana): Demonstrated significant reductions in MACE and hospitalization for heart failure.
  • DECLARE-TIMI 58 (dapagliflozin/Farxiga): While it didn’t show a significant reduction in MACE, it showed a substantial and statistically significant reduction in the risk of hospitalization for heart failure.
  • VERTIS-CV (ertugliflozin/Steglatro): Also showed a significant reduction in hospitalization for heart failure risk (a 30% relative risk reduction).

The consistent and powerful effect on reducing hospitalizations for heart failure across the class is particularly noteworthy and has led to their widespread adoption in cardiology.

The Multifaceted Mechanisms of SGLT2 Inhibitors

What makes these drugs so effective? The benefits go far beyond simple glucose lowering. Some of the proposed mechanisms that contribute to their cardioprotective and renoprotective effects:

  • Hemodynamic Effects: SGLT2 inhibitors have a mild diuretic effect, which helps reduce blood pressure by about 3-5 mmHg systolic. This is achieved through natriuresis, or the excretion of sodium and water, which reduces fluid volume and preload on the heart.
  • Reduced Glomerular Pressure: In the kidneys, these drugs reduce pressure within the glomerulus (the kidney’s filtering unit). This is a key theorized mechanism for their nephroprotective (kidney-protecting) effects, slowing the progression of diabetic kidney disease.
  • Metabolic Shifts: SGLT2 inhibitors promote a slight shift towards ketosis. The heart is a unique metabolic organ that can efficiently use ketones as a fuel source. This “super fuel” improves myocardial efficiency and function, especially in a stressed or failing heart.
  • Systemic Benefits: They also contribute to a modest weight loss (around 5-7 pounds), reduce inflammation, decrease oxidative stress, and may improve endothelial function and stabilize atherosclerotic plaques.
  • Improved Myocardial Energetics: By reducing the workload on the heart (via lower blood pressure and volume) and providing a more efficient fuel source (ketones), these drugs improve the overall energy balance and function of the heart muscle.

SGLT2 Inhibitors in Heart Failure and Kidney Disease

The benefits of SGLT2 inhibitors have been so profound that their use has expanded to patients without diabetes.

Heart Failure Trials

  • DAPA-HF and EMPEROR-Reduced: These trials studied dapagliflozin and empagliflozin, respectively, in patients with heart failure with reduced ejection fraction (HFrEF). Both showed a remarkable 25-26% relative risk reduction in the composite outcome of cardiovascular death or hospitalization for heart failure, regardless of whether the patients had diabetes.
  • EMPEROR-Preserved: This was the first trial to show a meaningful benefit in patients with heart failure with preserved ejection fraction (HFpEF), a very common and difficult-to-treat type of heart failure, particularly in older adults, women, and those with obesity. Empagliflozin reduced the primary composite endpoint by 21%.

Kidney Disease Trials

The evidence for kidney protection is just as compelling:

  • DAPA-CKD (dapagliflozin): This trial was stopped early due to overwhelming efficacy. It showed a 39% reduction in the risk of progression of kidney disease.
  • EMPA-KIDNEY (empagliflozin): Also demonstrated a significant 28% reduction in the risk of kidney disease progression or cardiovascular death.
  • CREDENCE (canagliflozin): Showcased a 30% reduction in the risk of kidney failure and cardiovascular events in patients with type 2 diabetes and kidney disease.

These trials have firmly established SGLT2 inhibitors as a cornerstone therapy for chronic kidney disease, even in patients without diabetes.

Understanding the Incretin Effect: TheBody’ss Natural Glucose Response System

For years, the management of type 2 diabetes centered on a few key strategies. However, a fascinating discovery completely shifted our understanding and opened the door to a new class of powerful therapies. Researchers observed a peculiar phenomenon: when people consumed glucose orally (by drinking it), their bodies produced a much more robust insulin response to lower blood sugar than when the same amount of glucose was administered intravenously (IV). This observation led them to a logical conclusion: there must be something happening in the gut when food is ingested that signals the pancreas to ramp up insulin production.
This phenomenon was termed the “incretin effect.” The “somethings” responsible were identified as gut hormones called incretins, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

  • The Process: When you eat, food travels to your stomach and intestines. Specialized cells in your gut (L-cells) detect the presence of nutrients and release GLP-1 and GIP into your bloodstream.
  • The Signal: These hormones then travel to the pancreas, where they act as messengers. They bind to receptors on pancreatic beta cells, stimulating the cells to release insulin.
  • The Result: This insulin release helps your body’s cells take up glucose, effectively lowering your blood sugar levels after a meal.

Crucially, this entire process is glucose-dependent. This means the incretins only stimulate insulin release when blood sugar levels are high, as they are after a meal. This built-in safety mechanism significantly reduces the risk of hypoglycemia (dangerously low blood sugar) when these pathways are targeted with medication, especially compared to older diabetes drugs.

The Blunted Incretin Effect in Type 2 Diabetes

One of the key physiological defects we see in patients with type 2 diabetes is a blunted or even absent incretin effect. Their bodies produce insufficient amounts of native GLP-1 in response to food. This deficiency contributes significantly to the hallmarks of the disease:

  • Poor Post-Meal Glucose Control: Without a strong incretin signal, the pancreas doesn’t release sufficient insulin after eating, resulting in prolonged periods of high blood sugar.
  • Dysregulated Appetite: Native GLP-1 also plays a critical role in promoting satiety, or the feeling of fullness. Low levels of this hormone can lead to a state of poor satiety, contributing to overeating and the obesity that is so often a comorbid condition with type 2 diabetes.
  • Excess Glucagon Secretion: GLP-1 normally helps suppress the release of another hormone called glucagon. Glucagon tells the liver to produce and release more sugar into the bloodstream (gluconeogenesis). In type 2 diabetes, this suppression is impaired, so the liver continues to release glucose even when blood glucose is already high.

Understanding this hormonal defect was the key that unlocked the development of GLP-1 receptor agonists—medications designed to mimic the action of our natural GLP-1 and restore these vital functions.

The Silent Threat: Hyperhomocysteinemia and its Impact on Your Health- Video

How GLP-1 Receptor Agonists Revolutionize Treatment

GLP-1 receptor agonists are a class of medications that bind to and activate GLP-1 receptors throughout the body, just as our native GLP-1 would, but they are engineered to last much longer. Their multifaceted mechanism of action addresses several core issues in type 2 diabetes and obesity simultaneously.

  • Stimulates Insulin Secretion: By activating pancreatic receptors, they prompt a glucose-dependent release of insulin, directly lowering blood sugar.
  • Inhibits Glucagon Secretion: They effectively tell the liver to stop producing excess sugar, which is a major contributor to high fasting and post-meal glucose levels.
  • Slows Gastric Emptying: This is a key mechanism for both glucose control and weight loss. By slowing down the rate at which food leaves the stomach, they prevent rapid spikes in blood sugar after meals. This delay also contributes to a prolonged feeling of fullness, which naturally leads to a decrease in overall food intake. This effect is often responsible for the common initial side effects like nausea, but it is also a primary driver of the medication’s success.
  • Increases Satiety: GLP-1 receptor agonists act directly on appetite centers in the brain, enhancing the feeling of fullness and reducing food cravings. This neurobiological effect is fundamental to the significant weight loss seen with these therapies.

Collectively, these actions lead to profound improvements in A1c, blood glucose, and body weight, tackling the metabolic dysfunction of type 2 diabetes at its source.

The Challenge of Over-Basalization: A Case Study

To truly understand the paradigm shift in diabetes care,let’ss consider a typical patient I might see in our clinic, whom we’ll call Tony. He represents a common challenge where adding a GLP-1 agonist is the superior strategy.

  • Patient Profile: Tony
  • Age: 62 years
  • Diagnosis: Type 2 Diabetes (11 years), Hyperlipidemia, Hypertension
  • Recent A1c: 8.2% (well above the target of <7.0%)
  • Kidney Health: Proteinuria (protein in the urine), an early sign of kidney damage.
  • Current Medications:
    • Degludec (basal insulin): 65 units daily
    • Metformin: 1000 mg twice daily
    • An SGLT2 inhibitor daily
    • A statin for cholesterol
  • An ARB for blood pressure
  • Physical Stats: Weight 220 lbs, Height 5’9 ” “, BMI 32.5 (classifies as obese)
  • Blood Sugar Patterns:
    • Fasting Glucose (morning): 15050 mg/dL
    • Postprandial Glucose (after meals/bedtime): 160-200 mg/dL

Tony’s case highlights a critical issue we call over-basalization. We’ve pushed his basal (long-acting) insulin dose to a high level, yet his A1c and post-meal sugars remain dangerously elevated. Research in pharmacokinetics reveals that once you exceed a certain dose of basal insulin, typically around 0.5 units per kilogram of body weight per day, you get diminishing returns. For Tony, who weighs 100 kg (220 lbs), this threshold is about 50 units. He is already on 65 units, pushing him past the point of modest glycemic effect and into the territory of significant side effects, primarily weight gain and a higher risk of hypoglycemia.
For a patient like Tony, the conventional next step might have been to add prandial (mealtime) insulin. While this can control post-meal spikes, it comes with a heavy price: a near-certainty of further weight gain and a significantly increased risk of hypoglycemia. Given his BMI of 32.5, adding more weight would only worsen his insulin resistance, creating a vicious cycle.
This is where the 2024 guidelines from the American Diabetes Association (ADA) strongly recommend adding a GLP-1 receptor agonist. It addresses multiple problems at once, moving beyond simple glucose lowering, weight loss, and cardiovascular protection, which are crucial for a high-risk patient like Tony.

Beyond Blood Sugar: The Cardiovascular and Renal Benefits of GLP-1s

Perhaps the most exciting development in the story of GLP-1 agonists is the overwhelming evidence of their protective effects on the heart and kidneys. Several landmark trials have established these powerful benefits:

  • The LEADER Trial (Liraglutide): This trial studied patients with type 2 diabetes and high cardiovascular risk. It showed a significant reduction in the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack, and non-fatal stroke.
  • The SUSTAIN-6 and PIONEER 6 Trials (Semaglutide): Both the injectable (SUSTAIN-6) and oral (PIONEER 6) forms of semaglutide were studied in patients with high cardiovascular risk. Both trials demonstrated a robust reduction in MACE, confirming the class effect.
  • The REWIND Trial (Dulaglutide): What made this trial unique was its focus on a broader population, including many patients who had risk factors for cardiovascular disease but had not yet had an event. It demonstrated that dulaglutide can be used for primary prevention, reducing the risk of a first cardiovascular event.
  • Tirzepatide (Mounjaro®, Zepbound™): This is a newer, highly potent dual GIP/GLP-1 receptor agonist. While its final CVOTs are still pending as of June 15, 2026, preliminary data suggest powerful cardiovascular benefits are likely.

More recently, the FLOW trial for semaglutide was stopped early because of overwhelmingly positive results showing a significant reduction in the risk of kidney disease progression (nephropathy). These findings are game-changers, solidifying the role of GLP-1 agonists as essential therapies for patients with or at high risk for heart and kidney disease.

Navigating Side Effects and Safety Considerations of GLP-1 Agonists

As with any potent medication, GLP-1 agonists are not without side effects. As clinicians, our job is to help patients navigate these challenges.

  • Gastrointestinal (GI) Issues: Nausea, vomiting, and diarrhea are common and caused by delayed gastric emptying. My clinical advice is always to “start low and go slow,” beginning with the lowest dose and titrating upwards gradually.
  • Dehydration and Acute Kidney Injury (AKI): Patients on these medications must drink plenty of water to prevent dehydration due to GI side effects.
  • Gallbladder Disease: Rapid weight loss, regardless of the method, is associated with an increased risk of gallstone formation.
  • Pancreatitis: Recent large-scale studies as of early 2025 have been reassuring, finding no statistically significant increase in the risk of pancreatitis and even suggesting a potential long-term risk reduction by improving metabolic health.
  • Thyroid C-Cell Tumors: These medications carry a black box warning due to an increased risk of thyroid C-cell tumors in rodents. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Muscle and Bone Loss: This is a feature of significant weight loss in general, not something specific to these drugs. This is where our integrative care becomes critical.

An Integrative Chiropractic Perspective on Metabolic Health

As a Doctor of Chiropractic with advanced training in functional medicine, I view the body as an integrated system. When I see a patient, I don’t just see a person with diabetes and heart disease. I see a complex interplay of systemic inflammation, metabolic dysfunction, and biomechanical stress. This is where our unique approach at Injury Medical Clinic PA provides immense value. The side effects and physiological changes associated with modern diabetes therapies are whole-body issues we can address.
Here’s how integrative chiropractic care fits into this new paradigm:

  1. Addressing Systemic Inflammation: Chronic inflammation is a root cause of both ASCVD and insulin resistance. Chiropractic adjustments have been shown to modulate the nervous system and can have a downstream effect on inflammatory pathways. By reducing spinal misalignments (subluxations), we can help normalize nerve function, which in turn influences the body’s inflammatory response.
  2. Promoting Physical Activity and Combating Muscle Loss: Exercise is a critical component of managing diabetes. However, many patients are limited by musculoskeletal pain. As chiropractors, our primary role is to improve biomechanical function, reduce pain, and restore mobility. Furthermore, with the rapid weight loss induced by GLP-1s, there is a risk of sarcopenia (muscle loss). We implement targeted strength training and rehabilitation protocols to preserve and build lean muscle mass. By treating underlying musculoskeletal issues, we empower patients to engage in the physical activity necessary for their metabolic health.
  3. Functional Medicine and Nutritional Counseling: My training as a Certified Functional Medicine Practitioner (CFMP) allows us to go deeper. We create personalized nutrition plans and recommend targeted supplementation to reduce inflammation, improve insulin sensitivity, and support cardiovascular health. To combat muscle loss, we ensure patients consume adequate protein to support muscle synthesis. This complements the work of medications by addressing the foundational lifestyle factors that drive disease.
  4. Stress Management and Autonomic Balance: The autonomic nervous system plays a huge role in regulating blood pressure, heart rate, and metabolic function. Chronic stress leads to a state of sympathetic (“fight-or-flight”) dominance, which can worsen hypertension and insulin resistance. Chiropractic care, along with techniques like breathwork and meditation, helps promote a parasympathetic (“rest-and-digest”) state, supporting better cardiovascular and metabolic regulation.

In our clinic, a patient would receive a comprehensive plan. Under the medical direction of Dr. Cardenas, they might be started on an SGLT2 inhibitor or a GLP-1 agonist. Simultaneously, my team would work with them on a personalized plan including chiropractic adjustments to improve mobility, an anti-inflammatory diet, and a progressive exercise program they can perform without pain. This integrated approach addresses the disease from multiple angles, leading to far better and more sustainable outcomes. This is the future of chronic disease management—a holistic, patient-centered, and team-based model of care.

References

SEO Tags: SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular disease, type 2 diabetes, chronic kidney disease, heart failure, integrative chiropractic care, functional medicine, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso, TX, ASCVD, risk reduction, metabolic health, incretin effect, over-basalization, tirzepatide, semaglutide, Mounjaro, Ozempic, diabetes management, A1c reduction, weight loss and diabetes, nephroprotection, cardioprotection, collaborative care, internal medicine, chiropractic, personal injury care, musculoskeletal health

Metabolic Health: A Comprehensive Guide to Understanding Obesity & Diabetes


Understand the effects of obesity and diabetes on overall wellness and take steps towards improvement in your metabolic health.

Abstract

Hello, I’m Dr. Alex Jimenez. In this educational post, we will embark on a comprehensive journey to understand the intricate and often overlapping physiological pathways of obesity, type 2 diabetes, and cardiovascular disease. I will present a patient-centered, first-person narrative describing how I approach these conditions through an integrative lens that blends chiropractic care, functional medicine, medical oversight, and rehabilitation. Drawing on the latest evidence-based research from leading experts, we will explore why treating obesity is not a matter of willpower but of addressing deep-seated biological dysregulation. We will delve into how inflammation, insulin resistance, and hormonal imbalances form a common pathological foundation for these chronic conditions. This discussion will highlight how modern pharmacotherapy targets these underlying mechanisms and why a chronic disease management model is essential for long-term success. Furthermore, I will explain how our unique multidisciplinary practice at Injury Medical Clinic PA integrates my chiropractic and functional medicine care with medical direction from our collaborative physician to provide a holistic and powerful treatment strategy for patients grappling with these complex cardiometabolic issues. We will break down the science, examine treatment guidelines, and illustrate how a synergistic approach, through real-world patient scenarios, can lead to profound improvements in health and quality of life.

Our Integrative Team: A Multidisciplinary Powerhouse

At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas, our philosophy is rooted in collaboration and integration. We believe that the most effective patient care comes from combining the strengths of different medical disciplines. I am Dr. Alexander Jimenez, and my credentials as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), board-certified Family Nurse Practitioner (FNP-BC), and advanced certifications in Functional Medicine (CFMP, IFMCP, ATN, CCST) allow me to view patient health through a multifaceted lens. My focus is on the structural, neurological, and functional aspects of wellness.

Functional Hormone, Thyroid, and Pellet Care Solutions

A cornerstone of our practice is our collaboration with Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is Board Certified in Internal Medicine with an impressive 40 years of experience (NPI #1164426749, Texas MD License #J2933). She serves as our Medical Director and Collaborative Physician, providing invaluable medical oversight, ensuring our protocols are evidence-based, and offering a deep understanding of internal medicine. This partnership between a chiropractor and an internist allows us to create a truly comprehensive care model, which is a standard and effective setup in integrative and injury care clinics.

Our team works in synergy to address the full spectrum of a patient’s needs. Here’s how our services fit together:

  • Medical Oversight (Dr. Cardenas, MD): Dr. Cardenas guides our medical protocols, confirms diagnoses, manages complex internal medicine conditions, reviews contraindications, and provides the necessary supervision for prescription therapies and advanced medical interventions. Her extensive experience is crucial for diagnosing and treating systemic diseases that often accompany musculoskeletal issues, such as diabetes and cardiovascular disease.
  • Chiropractic & Functional Medicine (Dr. Jimenez, DC, APRN, FNP-BC): I focus on restoring the body’s natural function. Through chiropractic adjustments, we can improve nervous system function, reduce pain, and enhance mobility. This is particularly important for patients with obesity, as pain can be a major barrier to physical activity. Through functional medicine, we dive deep to identify the root causes of dysfunction—be it gut dysbiosis, hormonal imbalances, or nutrient deficiencies—and create personalized plans involving nutrition, supplementation, and lifestyle changes to restore health from the inside out.
  • Rehabilitation & Personal Injury Care: Our team also includes specialists in physical rehabilitation who help patients recover from injuries and improve their functional capacity. This is a critical component of managing obesity, as structured exercise programs are essential for building muscle, improving metabolism, and supporting weight loss.

By integrating these disciplines, we don’t just treat symptoms; we treat the whole person. We address the structural, biochemical, and medical aspects of health simultaneously, providing a level of care far more effective than any single approach could be.

Understanding the Roots of Cardiometabolic Disease

In my clinical practice, we frequently manage conditions like dyslipidemia (abnormal blood fats), hypertension (high blood pressure), and various metabolic disorders. For decades, we have had a wide array of medications to manage the symptoms of these diseases. However, a crucial understanding has emerged from modern research: in many cases, obesity is the underlying root cause of these interconnected health problems.

Imagine a tree. The branches and leaves—the visible parts—are the diseases we commonly treat, such as heart disease, diabetes, and high blood pressure. But the roots, hidden beneath the surface, represent the foundational issue of obesity. These are the obesity-related complications and comorbidities that drive the majority of chronic diseases we face today.

The Misconception of Willpower: Obesity Causes Overeating

The human body possesses remarkably resilient, tightly regulated systems. If you become dehydrated, your kidneys conserve water, and you feel thirsty, prompting you to drink. In the same way, body weight is meant to be tightly regulated. However, in obesity, this regulatory system becomes dysfunctional. A groundbreaking shift in our understanding is this: Overeating doesn’t cause obesity; obesity causes overeating. Before a noticeable increase in fat mass (adiposity) occurs, a dysregulation of the endocrine system is already underway.

  • The First Hit: Hormonal Dysregulation
  • The process begins when something—be it genetics, environmental factors, or obesogenic medications—triggers the “on” switch for obesity. Once activated, the body’s production of hunger hormones (like ghrelin) increases, while the production of satiety hormones (like leptin and GLP-1) decreases. This creates a powerful biological drive for increased hunger and food intake.
  • The Second Hit: The Brain Defends a Higher Weight
  • The second, and perhaps more insidious, part of this pathology is that the brain begins to defend this new, higher body weight as its “normal.” This is the biological reality behind the frustrating cycle of weight regain. We now know it’s a consequence of dysregulated biology. The leading hypothesis is that this defense mechanism arises from inflammation in the hypothalamus, the brain’s control center for appetite and energy expenditure.

Obesity is an incredibly multifactorial disease, influenced by over 200 genes, endocrine-disrupting chemicals, poor sleep, and chronic stress.

The Pathophysiological Overlap of Diabetes and Heart Disease

To truly appreciate the interconnected nature of these conditions, let’s look at the underlying biology of each.

The Progression of Type 2 Diabetes

The pathophysiology of type 2 diabetes unfolds over years, beginning with insulin resistance, where cells become less responsive to insulin. To compensate, the pancreatic beta cells work overtime, producing more insulin. Eventually, these cells become exhausted, leading to impaired insulin secretion and elevated blood sugar (hyperglycemia), a condition known as prediabetes. As function declines further, type 2 diabetes is diagnosed. Beyond the pancreas, diabetes involves chronic inflammation, gut dysbiosis, and mitochondrial dysfunction, which contribute to “metabolic memory,” perpetuating the disease.

The Inflammatory Core of Cardiovascular Disease

Cardiovascular disease shares a similar common denominator: atherosclerosis, the buildup of plaque in the arteries, which is fundamentally driven by inflammation. A key player is nitric oxide (NO), a critical molecule that promotes vasodilation (widening of blood vessels) and reduces inflammation. In cardiovascular disease, nitric oxide availability decreases, leading to increased blood clotting, rampant inflammation, and endothelial dysfunction (damage to blood vessel linings). Metabolically, this leads to decreased glucose tolerance, elevated triglycerides, and increased oxidative stress.

The Unifying Theory: Inflammation, Lipotoxicity, and Mitochondrial Dysfunction

A clear picture emerges when we put it all together. The journey often begins with obesity, which fosters chronic inflammation and lipotoxicity (cellular damage from excess fats). This environment leads to mitochondrial dysfunction, impairing cellular energy production. This trifecta—inflammation, lipotoxicity, and mitochondrial dysfunction—creates a vicious cycle, driving the progression of obesity, insulin resistance, type 2 diabetes, and ultimately, cardiovascular disease.

Patient Journey: Stephen’s Case and Early Intervention for Prediabetes

To illustrate these concepts, let’s look at a patient I’ll call Stephen. His journey highlights how we apply this integrative model in practice.

Case Introduction and Risk Profile

Stephen is a 24-year-old male who sees me for follow-up regarding prediabetes and weight management. His A1C is 5.8%. He has a history of progressive weight gain, reaching a current weight of 250 lb with a BMI of 32.1 (class I obesity). His family history is significant for obesity, cardiovascular disease, and type 2 diabetes. His exam reveals central adiposity with a waist circumference of 41 inches, acanthosis nigricans, and skin tags, all signs of chronic hyperinsulinemia and insulin resistance.

From a physiological standpoint, Stephen exhibits a classic metabolic phenotype driven by:

  • Visceral adiposity: Central fat secretes pro-inflammatory adipokines and reduces adiponectin, impairing insulin sensitivity.
  • Hepatic insulin resistance: Increased liver glucose production and dyslipidemia, increasing his risk of metabolic dysfunction-associated steatotic liver disease (MASLD).
  • Endocrine signals: Altered leptin signaling and dysregulated GLP-1/GIP pathways that reduce satiety.
  • Biomechanics: Excess abdominal load increases lumbar lordosis and knee strain, areas where chiropractic integrative care can provide structural relief.

Evidence-Based Weight Loss Targets: Why Percentages Matter

I explained to Stephen that targeted weight-loss thresholds can dramatically change his health trajectory:

  • 3% weight loss: Measurable improvements in prediabetes and insulin sensitivity.
  • 10% weight loss: Robust changes in glucose control, lipids, and blood pressure.
  • 15%+ weight loss: Meaningful impact on type 2 diabetes, dyslipidemia, hypertension, sleep apnea, and MASLD.

Reducing adipose tissue lowers inflammatory cytokines, restores hormonal balance, and improves insulin signaling. These targets guide our decision on whether to use lifestyle changes alone or incorporate anti-obesity pharmacotherapy.

Patient Journey: Victoria – The Intersection of Menopause, Weight Gain, and Diabetes

Now, let’s explore a case representative of what many women experience during menopause.

Initial Presentation and History

Victoria, a 52-year-old woman, came to my clinic for a follow-up on her prediabetes and recent weight gain. She had recently entered menopause and gained 15 pounds in the past year. Her job is largely sedentary, her activity level has decreased, and she suffers from poor sleep due to night sweats.

Key Clinical Details:

  • BMI: 31.8 (class 1 obesity)
  • Fat Distribution: Central adiposity, with a neck circumference of 16 inches, a risk factor for sleep apnea.
  • Symptoms: Hot flashes, snoring, and high stress.

The Menopausal Transition and Metabolic Disruption

Victoria’s case is a classic example of the metabolic storm that accompanies menopause. The decline in estradiol leads to a rise in LDL cholesterol, decreased insulin sensitivity, a shift toward increased body fat, and endothelial dysfunction. These changes amplify cardiovascular risk. Fortunately, menopause hormone therapy (MHT) can mitigate many of these risks.

Laboratory Findings and Diagnosis

Victoria’s lab work confirmed our concerns. Her HbA1c had risen to 7.3%, diagnosing her with type 2 diabetes. Her HOMA-IR score, a measure of insulin resistance, was 4.7, indicating significant dysfunction.

Crafting a Patient-Centered Treatment Plan

Using a shared decision-making model, I asked Victoria, “What area would you like to target first?” She chose to try a higher dose of metformin and was intrigued by the idea of using a Continuous Glucose Monitor (CGM). The CGM provides invaluable real-time feedback that drives positive behavior changes. We also referred her to a menopause specialist.

When Victoria returned, her CGM data was eye-opening. Her average glucose was 173 mg/dL, and she was spending 34% of her time in hyperglycemia. Armed with this new insight, she committed to increasing her metformin, boosting protein intake, and eliminating sugar-sweetened beverages. A month later, after starting MHT, her sleep and hot flashes improved, but her weight loss was slow. At this point, I introduced semaglutide, a GLP-1 receptor agonist. One year later, she had lost 25 pounds, her BMI dropped from 31.8 to 27.5, and her metabolic markers improved dramatically. By treating her obesity, we achieved remission of her diabetes.

Patient Journey: Banny – Addressing Long-Standing Diabetes and Cardiovascular Risk

Our next case involves Banny, a 64-year-old man with a long and complex medical history, including type 2 diabetes for 25 years, hypertension, and a previous heart attack. His weight was 230 lbs (BMI of 36), and he struggled with food cravings and uncontrolled blood pressure.

The “5 C’s” of Obesity Treatment

When evaluating Banny, I used my “5 C’s” framework: Criteria, Contraindications, Combine, Cues/Causes, and Cost/Coverage. His history of cardiovascular disease made him a prime candidate for a GLP-1 receptor agonist like semaglutide, which has been shown to reduce the risk of major adverse cardiovascular events. I framed it as a way to not only manage his diabetes and weight but also reduce his risk for a second heart attack. He was immediately on board.

Uncovering Hidden Liver Disease

Banny’s labs showed a slightly elevated liver enzyme (ALT), prompting me to calculate his FIB-4 score, a non-invasive screen for liver fibrosis. His score of 2.25 placed him at high risk. This is critical, as up to 65% of people with type 2 diabetes have Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). I referred him to a gastroenterologist for further evaluation.

One year later, Banny had lost 23 pounds, and his HbA1c improved to 5.9%. He was diagnosed with liver fibrosis and started on a new medication. However, his weight loss had plateaued, and he struggled with intense food cravings. To address this, we added a low dose of topiramate at night to help control cravings, demonstrating a multi-pronged approach to modern obesity management.

Chiropractic Care & Metabolism *The Hidden Link*- Video

A Unified Approach to Treatment: Beyond “Eat Less, Move More”

The treatment guidelines for obesity, diabetes, and cardiovascular disease share a common foundation: a healthy eating plan, increased physical activity, and behavioral interventions. For diabetes and heart disease, we readily use medications, yet for obesity, there’s a misguided notion that patients must first “fail” lifestyle changes. This ignores the biological reality of the disease, where metabolic adaptation fiercely defends a higher body weight. Medications for obesity directly counteract the pathological hormonal and neurological changes driving the disease.

Nutrition Strategy: Creating Sustainable Metabolic Change

For patients like Stephen, we design a sustainable, enjoyable nutrition plan. This includes:

  • Caloric reduction: A deficit of 500- 750 kcal daily.
  • Carbohydrate management: Moderating refined carbs to improve insulin signaling.
  • Protein prioritization: To support satiety, thermogenesis, and muscle retention.
  • Fiber and non-starchy vegetables: To improve glycemic control and gut microbiome diversity.

Behavioral Health Strategy: Sleep, Stress, and Mood

Chronic stress and poor sleep worsen insulin resistance and weight gain by increasing cortisol and altering ghrelin and leptin levels. We screen for and address stress, mood, and sleep disorders, such as sleep apnea.

Physical Activity: Graded Movement and Functional Capacity

I provide evidence-based recommendations, such as 150-300 minutes/week of moderate-intensity activity and resistance training at least two days a week. For patients with pain, we incorporate referrals to physical and occupational therapy.

The Role of Modern Medications

The advent of GLP-1 receptor agonists (like liraglutide and semaglutide) and dual GIP/GLP-1 agonists (like tirzepatide) has been a game-changer. These medications mimic the body’s natural satiety hormones, helping patients achieve an average weight loss of 15-20% or more. Excitingly, many of these newer drugs, along with SGLT-2 inhibitors, have demonstrated significant cardiovascular benefits.

Recent multi-year research on tirzepatide has shown it can sustain a diabetes-free status in adults with prediabetes and deliver high-magnitude weight loss. For Stephen, after reviewing his options, we selected tirzepatide, starting at 2.5 mg weekly and titrating up. Two weeks later, he had lost 3 lbs. At one year, after reaching a 15 mg weekly dose, he had lost 50 lbs, his A1C was 5.4%, and his BMI dropped to 25.7.

An important part of my job is also avoiding obesogenic medications—drugs like certain sulfonylureas, insulins, and beta-blockers that can cause weight gain.

Chiropractic Integration: How Structural Care Supports Metabolic Therapy

While pharmacological and lifestyle interventions are central, integrative chiropractic care is a foundational element of our holistic approach.

  • Stress Reduction and Nervous System Regulation: Chronic stress is a major driver of metabolic dysfunction. My clinical observations show that patients with central obesity often develop thoracolumbar junction stiffness. Chiropractic adjustments can influence the autonomic nervous system, helping to shift the body from a “fight-or-flight” (sympathetic) state to a “rest-and-digest” (parasympathetic) state. This modulation can lower physiological stress, supporting better glycemic control (Jimenez, n.d.-a).
  • Improving Mobility and Reducing Pain: For patients like Stephen, Victoria, and Banny, joint pain and stiffness can be significant barriers to physical activity. By performing spinal and extremity adjustments, we can improve joint function, reduce pain, and make it easier for patients to engage in regular exercise. This facilitates adherence to activity prescriptions.
  • Optimizing Biomechanics: Correcting thoracolumbar junction dysfunction and sacroiliac joint mechanics can improve gait efficiency and reduce the energy cost of movement, making it easier for patients to increase their daily steps (Jimenez, n.d.-b).
  • Enhancing Sleep Quality: Alleviating neck and upper back tension can support airway mechanics and reduce nocturnal discomfort, which, in my clinical experience, can improve morning glucose stability.

The Chronic Disease Model: Why Treatment Must Be Long-Term

I want to end by reinforcing the most crucial concept: obesity is a chronic, relapsing disease that requires long-term management. The pathology of weight regain is a biological certainty, not a personal failing. When a person with obesity loses weight, the brain initiates a powerful counter-response: metabolism slows down, hunger hormones surge, and satiety hormones decrease. This creates an overwhelming drive to regain weight.

The STEP 1 trial extension starkly illustrates this: when participants stopped taking semaglutide, they began regaining weight, and their blood pressure and A1C levels started to creep back up (Wilding et al., 2022). We must apply the same chronic care model to obesity that we use for hypertension or diabetes. The goal is sustainable, long-term management to control the disease and prevent its devastating complications.

At Injury Medical Clinic, this philosophy guides us. By integrating chiropractic care to restore function, functional medicine to address root causes, and medical oversight from Dr. Cardenas to leverage the best of modern pharmacotherapy, we provide our patients with the comprehensive, long-term support they need to conquer these interconnected diseases and reclaim their health.

SEO Tags: Obesity Treatment, Type 2 Diabetes, Prediabetes Management, Cardiovascular Disease, Integrative Care, Chiropractic, Functional Medicine, Tirzepatide, GLP-1 GIP Agonists, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso Clinic, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Inflammation, Insulin Resistance, Metabolic Adaptation, Weight Regain, Cardiometabolic Health, Chronic Disease Management, Atherosclerosis, Nitric Oxide, Pharmacotherapy, Menopause and Weight Gain, Continuous Glucose Monitor, Semaglutide

References

Hormone Optimization for Wellness & Women’s Health

Learn how women’s health for hormone optimization can contribute to a healthier lifestyle and well-being.

Abstract

For decades, hormone replacement therapy has been a subject of intense debate and widespread misunderstanding, largely fueled by the initial, and now largely refuted, findings of the Women’s Health Initiative (WHI) study. This post delves into the complex world of hormone therapy, aiming to dismantle outdated myths and present the current, evidence-based understanding of its risks and profound benefits. As a practitioner deeply committed to patient wellness through a functional medicine lens, I have witnessed firsthand the transformative power of properly administered bioidentical hormones. Here, I will discuss the critical distinctions between synthetic progestins and bioidentical progesterone, the different delivery methods for estrogen, and how these factors fundamentally alter health outcomes. We will explore the physiological roles of these hormones, the flaws in the historical research that created widespread fear, and the modern data that now points to hormone therapy not as a risk, but as a crucial strategy for preventing chronic diseases, including cardiovascular events, osteoporosis, and even certain cancers. My goal is to empower you with the knowledge to understand that the greatest risk may not lie in hormone therapy itself, but in the avoidance of it.

Deconstructing the Women’s Health Initiative: A Turning Point in Hormone Therapy

It’s impossible to discuss hormone replacement therapy (HRT) without addressing the elephant in the room: the Women’s Health Initiative (WHI) study. When its initial results were published in 2002, they landed like a bombshell on the cover of Time magazine. The ensuing panic was immense. In my practice, the phone rang incessantly. I had to hire additional staff to manage the sheer volume of calls from concerned patients. Ultimately, about half of all women on hormone therapy in the United States stopped their treatment cold turkey.

Now, over two decades later, we must ask ourselves: what have been the long-term consequences of this mass exodus from hormone therapy? Have we seen the promised reductions in chronic disease?

  • Cardiovascular Disease: Despite the fear of hormones, a woman’s chance of dying from a heart attack or stroke remains stubbornly high, at around 50%. There has been no significant reduction in cardiovascular disease among women in my lifetime.
  • Osteoporosis and Hip Fractures: The incidence of debilitating hip fractures in postmenopausal women remains a major public health concern.
  • Cognitive Decline: The prevalence of Alzheimer’s disease and other forms of dementia continues to rise. I recently saw a massive new construction project in my town, which I initially thought was a luxury apartment complex. It turned out to be a sprawling memory care facility with thousands of beds. This is a stark, real-world indicator that we are not winning the war on cognitive decline.

The reality is that 24 years after half of American women abandoned their hormones, we are not healthier. In fact, we are arguably worse off.

The Flawed Science of the WHI Study

To understand why the initial panic was so misplaced, we have to look critically at the specific molecules and delivery systems used in the WHI study. The study did not use the hormones naturally produced by the human body. Instead, it used:

  1. Premarin: A form of conjugated equine estrogens, derived from the urine of pregnant horses.
  2. Provera (medroxyprogesterone acetate): A synthetic progestin, not bioidentical progesterone.
  3. Oral Delivery: Both substances were administered as pills.

This is a critical point. Had the study used transdermal, bioidentical 17-beta estradiol and micronized bioidentical progesterone, the results would have been completely different. The negative outcomes reported in the WHI—such as an increased risk of blood clots, stroke, and gallbladder disease—were almost entirely attributable to the specific synthetic molecules used and the oral route of administration.

When you swallow an estrogen pill, it undergoes a “first-pass metabolism.” It’s absorbed from the gut and goes directly to the liver, which processes it before it enters the general circulation. This process significantly increases the liver’s production of clotting factors, thereby increasing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE). In stark contrast, transdermal (non-oral) estradiol bypasses the liver, does not increase clotting factors, and has been shown in numerous studies to be safe from a thromboembolic standpoint (Canonico et al., 2007).

The Retraction and the Vindication of Estrogen

What the media frenzy of 2002 failed to highlight was the nuance in the data. Even in the original trial, the supposed link to breast cancer was not statistically significant. Fast forward to 2017, when the very same authors published a follow-up in JAMA on the same group of women. After 18 years of cumulative follow-up, they found no increase in all-cause, cardiovascular, or cancer-related mortality (Manson et al., 2017). In essence, they admitted their initial conclusions were wrong. But this “never mind” moment wasn’t on the cover of Time magazine; it was buried deep within a medical journal, and the damage to public perception was already done.

It gets even more compelling. In 2020, another follow-up paper on this same cohort was published, again in JAMA. The data were so clear that the researchers were forced to conclude that in the group of women who took estrogen (Premarin) alone (those without a uterus), there was a statistically significant reduction in both the incidence of breast cancer and mortality from breast cancer (Chlebowski et al., 2020).

Let that sink in. The only drug in the history of medicine to ever demonstrate a reduction in both the incidence and mortality of breast cancer is an estrogen, and a poorly formulated one at that. Why isn’t this front-page news? Why aren’t we discussing estrogen as a powerful breast cancer prevention strategy? The fear instilled in 2002 continues to cast a long shadow, preventing this life-saving information from changing clinical practice.

The Real Risks: Hormone Avoidance

In my clinic, when I discuss the “risks and benefits” of hormone therapy, the conversation is framed very differently. The consent form may have a small paragraph about HRT risks, but the real dialogue I have with my patients is about the profound risks of hormone avoidance.

What does it mean to “do menopause naturally”? It means accepting a future with a sharply increased risk of:

  • Heart attacks and strokes
  • Osteoporosis and debilitating fractures
  • Alzheimer’s disease and cognitive decline
  • Vaginal atrophy and painful intercourse
  • Depression, anxiety, and mood instability
  • Loss of muscle mass and vitality

Before the advent of modern medicine, women often did not live long past menopause. Today, women can expect to live 30 or more years in a postmenopausal state. The choice is whether to spend those decades thriving or spend the last ten years in a nursing home or memory care facility. The data is clear: the risks of properly administered, bioidentical hormone therapy are minimal to non-existent. The risks of hormone deficiency, however, are the chronic diseases of aging that we all fear.

The Symphony of Hormones: Understanding Receptors

The ancient Greeks used the word “”ormone” to mean “to set in motion.” It’s a perfect description. Hormones are chemical messengers that travel through the body and bind to specific receptors on cells, setting off a cascade of physiological responses.

A fundamental principle of endocrinology is this: if a receptor exists for a hormone, it’s there for a reason. The cell expects that hormone to be present and to deliver its message. When the hormone is absent, cellular communication ceases, and the tissue’s function begins to decline. This cannot be a healthy state.

  • Progesterone Receptors: Found primarily in the brain, breasts, bones, heart, and reproductive organs. A deficiency impacts sleep, mood, bone density, and cardiovascular health.
  • Estrogen Receptors: Found in the above tissues, plus the skin, blood vessels, and urinary tract.
  • Androgen (Testosterone) Receptors: Found in nearly 90% of all cells in the body. Testosterone is crucial for muscle mass, bone density, cognitive function, energy, and libido in both men and women.
  • Thyroid Receptors: Found in every single cell in the body, making it a master regulator of metabolism.

People often ask me which hormone is the “most important.” The truth is, they work synergistically. I often use the analogy of a cake and frosting. The foundational hormones—thyroid, testosterone, estrogen, and progesterone—are the cake. You must get the cake right first. Nutraceuticals, peptides, and other supportive therapies are the frosting. They are wonderful additions, but they can’t fix a poorly made cake. Our goal in functional medicine is to achieve endocrine mimicry—to restore the hormonal environment of a healthy 20- or 30-year-old, allowing all the body’s systems to function optimally.

Progesterone vs. Progestins: A Critical Distinction

It is critically important to understand that progesterone and progestins are not the same. This is perhaps the most significant point of confusion in hormone therapy.

  • Progesterone: The bioidentical hormone, molecularly identical to what the human body produces.
  • Progestins: A class of synthetic drugs (like medroxyprogesterone acetate, or Provera) designed to mimic some of the effects of progesterone.

Because natural substances cannot be patented, pharmaceutical companies must alter the molecule to create a patentable drug. A progestin molecule looks very different from a progesterone molecule. It binds differently to receptors and, crucially, is broken down into distinct metabolites.

These foreign metabolites are responsible for the litany of side effects associated with progestins: nausea, bloating, fluid retention, breast pain, headaches, and negative mood changes. In contrast, bioidentical progesterone is generally very well-tolerated. Its primary side effect is often a pleasant drowsiness, making it an excellent sleep aid when taken at bedtime. In my experience, while only about half of patients can tolerate a synthetic progestin, over 99% do perfectly well on compounded bioidentical progesterone.

The Role of Progesterone in a Woman’s Life

Progesterone is not just for protecting the uterus. Its most important function throughout the body is stabilization. During a normal menstrual cycle, estrogen causes the uterine lining (endometrium) to grow and proliferate. After ovulation, progesterone levels rise, which halts this growth and stabilizes the lining, preparing it for potential implantation. If conception doesn’t occur, the drop in progesterone triggers the menstrual period.

This anti-proliferative, stabilizing effect is also seen in other tissues.

  • Brain: Progesterone has calming, neuroprotective effects. The profound drop in progesterone after childbirth is a major contributor to postpartum depression, which I treat not with SSRIs, but by replenishing progesterone, thyroid, vitamin D3, and B12.
  • Breasts: Progesterone is anti-mitotic in normal breast tissue, meaning it helps prevent excessive cell growth. It is a key therapy I use for patients with painful, fibrocystic breasts. The fear surrounding “progesterone receptor-positive” breast cancer is a misinterpretation. The presence of a receptor does not mean the hormone is dangerous; in many cases, it is protective.

Clinical Pitfalls in Progesterone Prescribing

Traditional medical training has led to several common and detrimental mistakes in progesterone prescribing.

  1. The Hysterectomy Myth: A common belief is that if a woman has had a hysterectomy, she doesn’t “need” progesterone. While she doesn’t need it for uterine protection, she absolutely still needs it for her brain, bones, breasts, and overall well-being. Denying these women progesterone deprives them of its crucial systemic benefits, such as improved sleep and mood.
  2. Relying on Progesterone Creams: Progesterone is a large molecule. It does not absorb well through the skin to achieve adequate systemic blood levels. Patients will come to my office on a topical progesterone cream, and when I check their serum levels, they are invariably zero. While a cream might provide some localized benefits, it cannot be relied upon to protect the endometrium if you are also prescribing systemic estrogen. This is a critical point of medical-legal liability. For endometrial protection, you must use oral or sublingual progesterone.
  3. Ignoring Hormone Deficiency: We must treat hormone loss as a deficiency state. Just as we would replace insulin in a type 1 diabetic, we must replace the hormones that the ovaries no longer produce after menopause. This includes progesterone, regardless of whether a uterus is present.

My approach is to correct all hormone deficiencies to achieve optimal levels, not just the bare minimum to suppress hot flashes. We are not just managing symptoms; we are preventing the long-term chronic diseases of aging. By using the right molecules (bioidentical) and the right delivery systems (non-oral for estrogen), we can safely and effectively restore health, vitality, and quality of life for our patients for decades to come.

References

  • Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA, 324(4), 369–380. https://doi.org/10.1001/jama.2020.9482
  • Canonico, M., Oger, E., Plu-Bureau, G., et al. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation, 115(7), 840–845. https://doi.org/10.1161/CIRCULATIONAHA.106.642280
  • Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2017). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials. JAMA, 318(10), 927–938. https://doi.org/10.1001/jama.2017.11217

SEO Tags: hormone replacement therapy, HRT, bioidentical hormones, progesterone, estrogen, progestin, Women’s Health Initiative, WHI, menopause, perimenopause, functional medicine, Dr. Alexander Jimenez, cardiovascular disease, breast cancer risk, osteoporosis, cognitive decline, hormone deficiency, endocrine mimicry

Chiropractic Care Explained for Cardiovascular Diseases

Find out how chiropractic care can contribute to reducing cardiovascular disease while improving health and longevity for heart patients.

The Heart of Healing: How Chiropractic Care, Lycopene, and a Healthy Heart Diet Can Reduce Cardiovascular Disease Risk

Cardiovascular disease (CVD) is like the grim reaper of health problems, sneaking up on you while you’re binge-watching your favorite show or scarfing down a late-night taco. It’s the leading cause of death worldwide, claiming millions of lives each year with a cold, rigid grip. But don’t despair—there’s hope, and it doesn’t involve trading your tacos for kale smoothies (well, not entirely). At ChiroMed—Integrated Medicine in El Paso, TX, Dr. Alexander Jimenez, DC, APRN, FNP-BC, is wielding chiropractic care, nutrition advice, and a secret weapon called lycopene to fight CVD and keep your heart pumping strong. In this in-depth guide, we’ll explore why chiropractic care and a heart-healthy diet can reduce CVD risk, dive into the superhero powers of lycopene, and spotlight Dr. Jimenez’s expertise in personal injury cases. Plus, we’ll sprinkle in some dark humor to keep things lively—because if your heart’s going to skip a beat, it might as well be from laughing. Let’s get started.

Understanding Cardiovascular Disease: The Silent Stalker

Cardiovascular disease is like that creepy neighbor who never announces their arrival but always shows up at the worst time. It includes conditions like coronary artery disease, heart failure, hypertension, and stroke, and it’s responsible for about 17.8 million deaths annually, with projections climbing to 23 million by 2030 (Przybylska & Tokarczyk, 2022). Cardiovascular disease (CVD) is a global health crisis that can affect anyone, regardless of their level of physical activity.

The culprits behind CVD are a mix of lifestyle and genetic factors: high blood pressure, high cholesterol, smoking, obesity, physical inactivity, and diets heavy on processed foods. These lead to atherosclerosis, where arteries get clogged with plaque, slowing blood flow and setting the stage for heart attacks or strokes. Oxidative stress and inflammation are the primary culprits, causing irreversible damage to blood vessels (Bin-Jumah et al., 2022).

But here’s the kicker: CVD doesn’t just mess with your heart. It can also disrupt your musculoskeletal system. Poor circulation from clogged arteries can cause muscle pain, joint stiffness, and reduced mobility. Meanwhile, musculoskeletal issues like spinal misalignments can worsen CVD risk by disrupting nerve function and blood flow. Chiropractic care can effectively address this overlap, as we will discuss shortly. Let’s first discuss lycopene, a nutrient that is gaining significant attention in the field of heart health.

References

  • Przybylska, S., & Tokarczyk, G. (2022). Lycopene in the prevention of cardiovascular diseases. International Journal of Molecular Sciences, 23(4), 1957. https://doi.org/10.3390/ijms23041957
  • Bin-Jumah, M. N., Nadeem, M. S., Gilani, S. J., et al. (2022). Lycopene: A natural arsenal in the war against oxidative stress and cardiovascular diseases. Antioxidants, 11(2), 232. https://doi.org/10.3390/antiox11020232

Lycopene: The Heart’s Caped Crusader

Lycopene is like the Superman of nutrients, soaring through your bloodstream to save your heart from the clutches of oxidative stress and inflammation. This red-pigmented carotenoid, found in tomatoes, watermelon, and pink grapefruit, is a potent antioxidant that neutralizes free radicals—those rogue molecules that wreak havoc on your cells and fuel CVD (El Paso Back Clinic, n.d.). Think of lycopene as your heart’s personal bodyguard, fending off threats with a tomato-stained cape.

How Lycopene Protects Your Heart

Lycopene’s heart-protective powers are backed by science and a bit of swagger. Here’s how it works:

  1. Antioxidant Superpowers: Lycopene is a heavyweight in the antioxidant world, with a singlet-oxygen quenching ability twice that of beta-carotene and ten times that of vitamin E (Gajendragadkar et al., 2014). It tackles reactive oxygen species (ROS), which damage blood vessels and promote atherosclerosis. Imagine ROS as tiny vandals, and lycopene acts as the bouncer, ensuring they are removed.
  2. Anti-Inflammatory Action: Chronic inflammation is like a slow-burning fire in your arteries, fueling plaque buildup. Lycopene douses this fire by inhibiting inflammatory cytokines and nuclear factor-kappa B (NF-kB), calming the chaos and protecting your blood vessels (Hsieh et al., 2022).
  3. Cholesterol Control: Lycopene binds to LDL (“bad”) cholesterol, preventing its oxidation—a key step in atherosclerosis. Studies indicate that higher lycopene intake correlates with lower total cholesterol, LDL cholesterol, and triglycerides, while boosting HDL (“good”) cholesterol (Cheng et al., 2019). It’s akin to firmly confronting your cholesterol levels.
  4. Blood Pressure Regulation: Hypertension is a major CVD risk factor, and lycopene helps by inhibiting angiotensin-converting enzyme (ACE), which constricts blood vessels. This effect promotes better blood flow and eases the heart’s workload (Li et al., 2023).
  5. Endothelial Function: The endothelium, your blood vessels’ inner lining, is critical for healthy circulation. Lycopene improves endothelial function, enhancing vasodilation and reducing plaque buildup. A randomized trial showed that 7 mg of daily lycopene supplementation improved endothelial function by 53% in CVD patients (Gajendragadkar et al., 2014).
  6. Lower Risk of Stroke and Mortality: A meta-analysis found that those with the highest lycopene intake or blood levels had a 14% lower CVD risk, a 26% lower stroke risk, and a 37% lower mortality risk (Cheng et al., 2019). Lycopene essentially provides your heart with a VIP pass to longevity.

Where to Find Lycopene

You don’t need to drown in tomato sauce to get lycopene (though it might make for an interesting dinner party). It’s found in:

  • Tomatoes and tomato products (sauce, juice, ketchup)
  • Watermelon
  • Pink grapefruit
  • Papaya
  • Guava

Processed tomato products have higher bioavailability because heat treatment releases lycopene from plant fibers (Przybylska & Tokarczyk, 2022). Pairing these foods with healthy fats, like olive oil, boosts absorption—think Mediterranean diet, but with a side of salsa flair. Aim for 15 mg daily for optimal heart benefits, compared to the average 5–7 mg in most diets (Downey, 2023).

Lycopene in Action

Think of your arteries as a bustling highway. Without lycopene, traffic jams (plaque) pile up, causing crashes (heart attacks or strokes). Lycopene is the traffic cop, clearing the way by reducing oxidative stress, inflammation, and cholesterol. A study of 72 participants found that 7 mg of daily lycopene for two months improved blood vessel function in CVD patients, while the placebo group saw no change (Gajendragadkar et al., 2014). It’s like a tune-up for your heart, no mechanic required.

References

Eating Right To Feel Better- Video

Chiropractic Care: Your Heart’s Unexpected Ally

You might think chiropractic care is just about cracking backs and soothing neck pain, but it’s more like a secret weapon for your whole body—including your heart. At ChiroMed, Dr. Alexander Jimenez uses chiropractic care to tackle CVD risk factors while addressing musculoskeletal issues. It’s like giving your body a full-service tune-up, minus the oil change.

The Spine-Heart Connection

Your spine is the backbone (pun intended) of your health. Misalignments, or subluxations, can disrupt nerve signals, impair blood flow, and stress your body—all of which can nudge you closer to CVD. Here’s how:

  • Nerve Interference: The autonomic nervous system, which controls heart rate and blood pressure, can be thrown off by spinal misalignments, especially in the upper thoracic or cervical spine. Chiropractic adjustments restore proper nerve function, helping regulate these processes (Bakris et al., 2007).
  • Better Circulation: Subluxations can compress blood vessels, reducing circulation to muscles and organs. Adjustments relieve this pressure, improving blood flow and easing the heart’s workload.
  • Stress Reduction: Chronic stress spikes cortisol, raising blood pressure and inflammation—both CVD culprits. Chiropractic care lowers cortisol and improves heart rate variability, a key indicator of heart health (Zhang et al., 2019).

How Chiropractic Care Tackles CVD Risk

At ChiroMed, chiropractic care goes beyond adjustments. Dr. Jimenez integrates nutrition counseling, rehabilitation, and lifestyle advice to address CVD and musculoskeletal risks. Here’s how it works:

  1. Blood Pressure Control: A 2007 study showed that upper cervical adjustments reduced blood pressure as effectively as two antihypertensive drugs in patients with stage 1 hypertension (Bakris et al., 2007). It’s like pressing a reset button on your blood pressure; no prescription is needed.
  2. Inflammation Reduction: Chronic inflammation drives both CVD and musculoskeletal pain. Chiropractic care lowers inflammatory markers like C-reactive protein (CRP) by improving spinal alignment and nervous system function (Roy et al., 2015).
  3. Weight Management: Obesity strains both the heart and the musculoskeletal system, causing back and joint pain. ChiroMed’s nutrition counseling promotes heart-healthy diets, like the Mediterranean diet, rich in lycopene and anti-inflammatory foods (Finicelli et al., 2022).
  4. Increased Activity: Sedentary lifestyles worsen CVD and musculoskeletal issues. Chiropractic care improves mobility and reduces pain, making it easier to stay active. Dr. Jimenez’s rehab programs are tailored to keep you moving.
  5. Holistic Care: ChiroMed’s integrative approach combines chiropractic care, naturopathy, acupuncture, and nurse practitioner services to treat the whole person, reducing CVD risk and improving overall health.

Dark Humor Break: The Spine-Heart Soap Opera

Picture your spine and heart as stars in a cheesy soap opera. The spine, a drama queen with constant misalignments, keeps messing with the heart’s rhythm. The heart, overworked and underpaid, just wants to pump in peace. Enter Dr. Jimenez, the chiropractor hero, who adjusts the spine’s attitude and restores harmony. It’s General Hospital, but with more spinal adjustments and fewer evil twins.

References

  • Bakris, G., Dickholtz, M., Meyer, P. M., et al. (2007). Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: A pilot study. Journal of Human Hypertension, 21(5), 347–352. https://doi.org/10.1038/sj.jhh.1002133
  • Zhang, J., Dean, D., Nosco, D., et al. (2019). Effect of chiropractic care on heart rate variability and pain in a multisite clinical study. Journal of Manipulative and Physiological Therapeutics, 42(6), 403–411. https://doi.org/10.1016/j.jmpt.2019.02.006
  • Roy, R. A., Boucher, J. P., & Comtois, A. S. (2015). Inflammatory response following a short-term course of chiropractic treatment in patients with chronic low back pain. Journal of Chiropractic Medicine, 14(3), 171–179. https://doi.org/10.1016/j.jcm.2015.06.002
  • Finicelli, M., Di Salle, A., Galderisi, U., et al. (2022). The Mediterranean diet: An update of the clinical trials. Nutrients, 14(14), 2956. https://doi.org/10.3390/nu14142956

A Healthy Heart Diet: Fueling Your Body Right

If your diet is more fast food than fresh produce, it’s time to give your plate a makeover. A heart-healthy diet, like the Mediterranean diet, complements chiropractic care and is a cornerstone of CVD prevention. At ChiroMed, Dr. Jimenez emphasizes nutrition, with lycopene-rich foods as a key player.

Key Elements of a Healthy Heart Diet

  1. Lycopene-Rich Foods: Add tomatoes, watermelon, and pink grapefruit to your meals. Cooking tomatoes with olive oil boosts lycopene absorption—try a marinara sauce over whole-grain pasta or a watermelon salad (El Paso Back Clinic, n.d.).
  2. Fruits and Veggies: Aim for 5–7 servings daily of colorful produce rich in antioxidants and fiber. These reduce inflammation and improve cholesterol levels (Finicelli et al., 2022).
  3. Whole Grains: Swap white bread for quinoa, brown rice, or oats. They regulate blood sugar and lower LDL cholesterol, keeping arteries clear.
  4. Healthy Fats: Embrace olive oil, avocados, and nuts. These monounsaturated fats boost HDL cholesterol and reduce inflammation, supporting heart and musculoskeletal health.
  5. Lean Proteins: Choose fish, poultry, or legumes over red meat. Omega-3-rich fish like salmon lower triglycerides and CVD risk.
  6. Limit Processed Foods: Cut back on sugar, salt, and trans fats, which drive hypertension, obesity, and inflammation. Think of processed foods as your heart’s archenemy.

Small Changes, Big Impact

Dr. Jimenez’s clinical insights focus on sustainable changes:

  • Start Small: Add one lycopene-rich food daily, like tomato juice or guava.
  • Meal Prep: Make lycopene-packed meals, like tomato soup, ahead of time.
  • Snack Smart: Swap chips for veggies with hummus or lycopene-rich papaya.
  • Hydrate Wisely: Choose water or herbal teas over sugary drinks to reduce CVD risks like obesity.

Dark Humor Moment: The Tomato Takeover

If lycopene were a person, it’d be that friend who brings tomato-based dishes to every potluck, shouting, “Eat me! I’m heart-healthy!” while everyone else hides their burgers. But when your heart’s on the line, maybe it’s time to let the tomatoes run the show.

References

Personal Injury in El Paso: Dr. Jimenez’s Expertise

El Paso’s busy streets and active workforce make personal injuries—car accidents, workplace mishaps, or slips and falls—all too common. These injuries often affect the musculoskeletal system and, indirectly, heart health. Dr. Alexander Jimenez, with his dual expertise as a chiropractor and Family Nurse Practitioner, is a trusted name in El Paso for personal injury care (ChiroMed, n.d.).

The Impact of Personal Injuries

Injuries like whiplash or back pain can:

  • Cause Musculoskeletal Damage: Sprains, strains, or fractures limit mobility and increase pain, making physical activity—a key CVD prevention tool—challenging.
  • Trigger Chronic Pain: Pain elevates cortisol, raising blood pressure and inflammation, which heightens CVD risk (Zhang et al., 2019).
  • Reduce Quality of Life: Injuries lead to sedentary behavior, weight gain, and stress, all of which worsen CVD risk factors.

Dr. Jimenez’s Approach

Dr. Jimenez bridges medical and legal needs with:

  1. Advanced Imaging: MRI, X-rays, and ultrasound pinpoint injuries, from soft tissue damage to subluxations, ensuring accurate treatment and legal documentation (ChiroMed, n.d.).
  2. Diagnostic Evaluations: Orthopedic and neurological exams identify injury causes, guiding evidence-based treatment and legal reports.
  3. Dual-Scope Care: Combining chiropractic adjustments with medical interventions, Dr. Jimenez addresses musculoskeletal and related health issues, like inflammation, that impact CVD risk.
  4. Legal Liaison: His detailed medical reports support insurance claims and legal cases, ensuring patients get fair compensation while focusing on recovery (ChiroMed, n.d.).
  5. Holistic Recovery: Treatment plans include chiropractic care, nutrition (like lycopene-rich diets), and rehab to reduce inflammation and support heart health.

Why Dr. Jimenez Stands Out

With over 20 years of experience, Dr. Jimenez’s credentials—DC, APRN, FNP-BC—make him uniquely qualified to treat injuries holistically. His work, highlighted on LinkedIn (Jimenez, n.d.) and ChiroMed’s site, reflects his commitment to patient-centered care.

Dark Humor Interlude: The Injury Irony

Getting rear-ended in El Paso traffic is bad enough, but when your back pain starts conspiring with your heart to ruin your day, it’s like your body’s playing a twisted game of whack-a-mole. Dr. Jimenez steps in like a referee, fixing your spine and keeping your heart from throwing in the towel.

References

Clinical Insights from Dr. Jimenez: Small Steps, Big Wins

Dr. Jimenez’s philosophy at ChiroMed is about empowering patients with small, sustainable changes:

  • Daily Movement: Walk or stretch for 10–15 minutes daily to boost circulation and support musculoskeletal health.
  • Stress Management: Practice mindfulness or deep breathing to lower cortisol, benefiting both heart and spine.
  • Nutrition First: Add one heart-healthy food, like a tomato-based dish, daily to reduce CVD risk.
  • Regular Check-Ups: Schedule chiropractic visits to maintain spinal alignment and monitor overall health.

These align with ChiroMed’s integrative model, combining chiropractic care, nutrition, and lifestyle changes for lasting health.

Conclusion: A Serious Note on Heart Health

While we’ve had fun with some dark humor to keep things light, cardiovascular disease is a serious matter. It’s a leading killer, but chiropractic care, a lycopene-rich diet, and Dr. Jimenez’s expertise offer a powerful, holistic defense. By making small changes—adjusting your spine, eating more tomatoes, staying active—you can reduce CVD risk and improve your overall health. Dr. Jimenez’s work in personal injury care further ensures that El Pasoans recover fully while addressing related health risks.

Disclaimer: This blog post is for educational purposes only and is not a substitute for professional medical advice. Consult a qualified healthcare provider, like Dr. Jimenez, before starting any treatment or dietary changes. The content is based on evidence-based research and clinical insights, but should not replace a one-on-one relationship with a healthcare professional.

References

Tofu Benefits: Nutrition and Cooking Tips

Uncover the health benefits of tofu. This nutritious ingredient is great for both your taste buds and your well-being.

Introduction

As a nurse practitioner with over two decades of clinical experience in physical and functional medicine, I’ve witnessed firsthand the transformative power of food as medicine. In particular, the role of plant-based proteins like tofu has grown increasingly significant in evidence-based interventions aimed at reducing cardiovascular risk.

From managing hypertension and dyslipidemia to reducing systemic inflammation, a heart-healthy diet is one of the most accessible and sustainable lifestyle changes patients can make. One often-underappreciated food with robust cardioprotective properties is tofu. In this article, we’ll explore the science-backed benefits of tofu, its role in functional cardiovascular care, and practical ways to integrate it into a heart-smart diet.

Why Functional Nutrition Matters for Cardiovascular Health

The heart doesn’t function in isolation—it works in concert with every other system in the body. Functional medicine recognizes that cardiovascular issues often stem from a constellation of root causes: chronic inflammation, oxidative stress, hormonal imbalances, dysregulated blood sugar, and nutrient deficiencies, just to name a few.

Rather than isolating nutrients or treating lab values in a vacuum, functional nutrition focuses on synergy—how whole foods interact with body systems to optimize health. Tofu, with its impressive nutrient density and anti-inflammatory profile, fits seamlessly into this paradigm.

What Is Tofu? A Nutritional Powerhouse from the Soybean

Tofu, also known as bean curd, is a protein-rich food derived from soybeans. It has been a staple in East Asian diets for over 2,000 years and is gaining popularity in the West for good reason.

To produce tofu, soybeans are soaked, blended, and strained into a soy milk, which is then coagulated using calcium or magnesium salts and pressed into blocks. This process preserves the soybean’s rich content of protein, calcium, iron, and bioactive compounds.

Unlike ultra-processed meat substitutes, tofu is a minimally processed, whole food source of plant protein that aligns with the foundational principles of a heart-healthy, anti-inflammatory diet.

Nutritional Profile of Tofu (Per 116g Serving of Firm Tofu)

  • Calories: 88
  • Protein: 9g
  • Fat: 6g (mostly unsaturated)
  • Saturated Fat: 0.8g
  • Carbohydrates: 2.2g
  • Fiber: 0.3g
  • Sodium: 8mg
  • Potassium: 140mg
  • Iron: 34% Daily Value (DV)
  • Calcium: 40% DV
  • Magnesium: 8% DV
  • Vitamin B6: 5% DV

Tofu also contains all nine essential amino acids, making it a complete protein—an important consideration for those transitioning away from animal products.

The Healing Diet: Combat Inflammation & Embrace Wellness- Video

The Cardiovascular Benefits of Tofu: What the Science Says

1. Lowering LDL Cholesterol

A pivotal meta-analysis published in the Journal of Nutrition (Messina, 2016) confirmed the LDL-lowering effects of soy protein. Tofu, being rich in soy protein, can help reduce low-density lipoprotein (LDL) cholesterol, often referred to as “bad” cholesterol. By displacing saturated fat and dietary cholesterol from animal proteins, tofu supports healthier lipid profiles.

2. Anti-Inflammatory and Antioxidant Properties

Tofu is rich in isoflavones, naturally occurring phytoestrogens found in soybeans. Isoflavones like genistein and daidzein have antioxidant properties and may inhibit inflammation at the endothelial level—critical for patients with atherosclerosis or at risk for coronary artery disease. According to Rizzo et al. (2023), these compounds help maintain vascular flexibility and may inhibit platelet aggregation, reducing clot risk.

3. Blood Pressure Regulation

Magnesium, potassium, and calcium—key electrolytes found in tofu—are all essential for regulating blood pressure. These nutrients support vascular tone and optimize endothelial function. Additionally, substituting animal-based protein with tofu helps reduce overall sodium intake, further supporting blood pressure goals.

4. Weight and Metabolic Control

With only 88 calories per serving and a high satiety value, tofu is a strategic food for weight management—an important factor in controlling cardiovascular risk. The protein-fiber-fat ratio makes it ideal for glycemic regulation and preventing insulin resistance.

5. Improved Lipid Profiles and Reduced Coronary Risk

Longitudinal studies have demonstrated that plant-based diets rich in soy protein improve HDL/LDL ratios and reduce triglycerides, especially when tofu is used to replace red meat or processed meats. According to Erdman (2000), soy-based interventions can reduce coronary heart disease risk by as much as 20% over time when combined with other healthy lifestyle changes.

Types of Tofu and Their Culinary Uses

Tofu’s versatility is one reason it’s so easy to integrate into a heart-healthy diet. Understanding its different textures can help patients and practitioners alike explore creative and satisfying meal planning.

  • Silken Tofu: Soft, custard-like texture. Excellent in smoothies, sauces, and desserts.
  • Soft Tofu: Slightly firmer than silken. Ideal for soups and gentle sautés.
  • Firm Tofu: Maintains structure well. Great for stir-fries, curries, and grilling.
  • Extra-Firm Tofu: Dense and chewy. Best for baking, frying, or as a meat substitute in hearty recipes.
  • Fermented Tofu: A flavorful condiment used in East Asian dishes. Contains probiotics and can support gut health.

Each form can be marinated, baked, crumbled, or pureed—making tofu a culinary chameleon and nutrient-rich addition to any cardiovascular prevention strategy.

Is Tofu a Reliable Protein Source for Cardiovascular Patients?

Yes—and not just for vegans or vegetarians. One of the biggest concerns in reducing animal protein intake is whether patients will meet their protein needs. Tofu alleviates this concern by offering a complete amino acid profile.

Furthermore, because tofu contains very little saturated fat and zero dietary cholesterol, it aligns with AHA (American Heart Association) guidelines for protein sources that support cardiac health. Tofu also promotes lean muscle maintenance, critical for older adults at risk for sarcopenia—a condition that compounds cardiovascular vulnerability.

Functional Medicine Tips: How to Add Tofu to a Heart-Healthy Diet

Transitioning to a more plant-based approach doesn’t have to be intimidating. Here are simple, evidence-informed ways to incorporate tofu:

  1. Tofu Scrambles: Replace eggs with crumbled firm tofu, turmeric, and vegetables for a cholesterol-free breakfast.
  2. Stir-Fries: Toss cubed tofu with olive oil, garlic, and cruciferous vegetables like broccoli or bok choy.
  3. Tofu Bowls: Combine baked tofu with quinoa, avocado, leafy greens, and tahini for a nutrient-dense lunch.
  4. Soups and Stews: Add soft tofu to miso or vegetable-based soups for added protein and satiety.
  5. Smoothies: Blend silken tofu with berries, flaxseed, and almond milk for a protein-packed snack.
  6. Marinated and Grilled: Let tofu absorb anti-inflammatory marinades (like ginger-garlic-tamari) before grilling.

Encourage patients to explore international cuisines—particularly Japanese, Korean, and Thai recipes—that have normalized tofu as a central protein source for centuries.

Addressing Common Concerns About Soy

Despite its benefits, soy has faced scrutiny—largely due to misconceptions around phytoestrogens. However, clinical research consistently shows that moderate soy intake is safe and beneficial for most populations, including breast cancer survivors and men with prostate concerns.

In fact, population studies in East Asia demonstrate lower rates of hormone-sensitive cancers and cardiovascular disease in populations consuming soy regularly. As with any food, balance and moderation are key.

Final Thoughts: Tofu as a Functional Ally for Cardiovascular Health

Tofu isn’t just a trend—it’s a time-tested, nutrient-dense, cardioprotective food with substantial clinical value. As healthcare providers, we should not underestimate the power of simple dietary substitutions. Replacing saturated fat-rich meats with plant-based proteins like tofu can reduce cardiovascular burden, support metabolic resilience, and enhance quality of life.

From a functional medicine lens, tofu exemplifies the concept of food as a therapeutic tool. Its ability to modulate inflammation, support endothelial function, and provide sustainable, complete protein makes it a cornerstone in any heart-healthy nutrition plan.

Injury Medical & Functional Medicine Clinic

We associate with certified medical providers who understand the importance of assessing individuals dealing with cardiovascular issues and are looking for natural alternatives to incorporate plant-based foods into a healthy diet. When asking important questions to our associated medical providers, we advise patients to incorporate tofu into their diet to reduce the effects of cardiovascular disorders related to the body. Dr. Alex Jimenez, D.C., uses this information as an academic service. Disclaimer.

References

Dang, Y., Ren, J., Guo, Y., Yang, Q., Liang, J., Li, R., Zhang, R., Yang, P., Gao, X., & Du, S. K. (2023). Structural, functional properties of protein and characteristics of tofu from small-seeded soybeans grown in the Loess Plateau of China. Food Chem X, 18, 100689. https://doi.org/10.1016/j.fochx.2023.100689

Erdman, J. W., Jr. (2000). AHA Science Advisory: Soy protein and cardiovascular disease: A statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation, 102(20), 2555-2559. https://doi.org/10.1161/01.cir.102.20.2555

Eze, N. M., Okwume, U. G., Eseadi, C., Udenta, E. A., Onyeke, N. G., Ugwu, E. N., Akubue, B. N., Njoku, H. A., & Ezeanwu, A. B. (2018). Acceptability and consumption of tofu as a meat alternative among secondary school boarders in Enugu State, Nigeria: Implications for nutritional counseling and education. Medicine (Baltimore), 97(45), e13155. https://doi.org/10.1097/MD.0000000000013155

Messina, M. (2016). Soy and Health Update: Evaluation of the Clinical and Epidemiologic Literature. Nutrients, 8(12). https://doi.org/10.3390/nu8120754

Montgomery, K. S. (2003). Soy protein. J Perinat Educ, 12(3), 42-45. https://doi.org/10.1624/105812403X106946

Rizzo, J., Min, M., Adnan, S., Afzal, N., Maloh, J., Chambers, C. J., Fam, V., & Sivamani, R. K. (2023). Soy Protein Containing Isoflavones Improves Facial Signs of Photoaging and Skin Hydration in Postmenopausal Women: Results of a Prospective Randomized Double-Blind Controlled Trial. Nutrients, 15(19). https://doi.org/10.3390/nu15194113

Disclaimer